Browse the evidence

Indiscriminate use of Semaglutide for weight loss without medical supervision poses significant health risks, including gastrointestinal distress, hypoglycemia, and potential renal or pancreatic complications.

Do not use Semaglutide for weight loss without a doctor's prescription and monitoring. The risks, including severe stomach issues and low blood sugar, are significant when used indiscriminately. Sustainable weight loss requires lifestyle changes, not just medication.

GIP receptor antagonism promotes weight loss and protects against diet-induced obesity, potentially by enhancing leptin sensitivity in the hypothalamus and reducing lipid storage in adipose tissue.

Research indicates that blocking the GIP receptor (antagonism) can also lead to weight loss, possibly by improving how your body responds to leptin and reducing fat storage. This is an emerging area of treatment, with some drugs in clinical trials combining GIP antagonism with GLP-1 agonism for enhanced effects.

Higher starch intake is associated with lower levels of specific plasma proteins (adrenomedullin, IL1ra, FABP4, leptin, CCL20) that are themselves positively associated with increased CVD and mortality risk.

This finding suggests that moderate starch intake may help regulate inflammatory and adiposity-related proteins. However, since the association weakened after adjusting for BMI, maintaining a healthy weight is likely the primary driver of these benefits.

Off-label prescribing of semaglutide (Ozempic) for weight loss causes significant supply shortages for patients with type 2 diabetes who require the medication for its FDA-approved indication.

If you are considering Ozempic for weight loss, understand that it is a serious medication, not a cosmetic shortcut. It works by mimicking hormones that regulate hunger, but stopping it often leads to significant weight regain. Be aware that high demand for off-label use has caused shortages for people who need it for diabetes, so discuss ethical access and long-term sustainability with your doctor before starting.

GLP-1 receptor agonist therapy improves tear production and tear film stability in patients with type 2 diabetes compared to non-GLP-1 RA therapies.

If you have Type 2 Diabetes and are considering or using GLP-1 RAs (like semaglutide or dulaglutide), this research suggests these medications might actually help keep your eyes moist and stable compared to other diabetes drugs. While this doesn't replace standard dry eye treatments, it is a potential benefit to discuss with your doctor, especially if you suffer from dry eye symptoms.

Network pharmacology analysis suggests that the synergistic mechanism of combined exercise and medication involves the IL1B-STAT3 inflammatory axis and SIRT1/CD36 lipid metabolism network.

This is a mechanistic hypothesis. It suggests that combining exercise and medication may work by reducing inflammation (IL1B-STAT3) and improving lipid metabolism (SIRT1/CD36).

Phentermine and Phentermine/Topiramate are associated with a higher incidence of acute kidney injury (AKI) and kidney injury events compared to other anti-obesity medications, and require dose adjustments in CKD stages 3+.

Avoid stimulant-based weight loss drugs like phentermine if you have CKD, especially stage 3 or higher. They carry a higher risk of kidney injury and require dose adjustments. GLP-1 medications are a safer and more effective option for protecting your kidneys while losing weight.

Dual GLP-1/glucagon agonists (e.g., cotadutide, pemvidutide) provide greater reductions in liver fat and fibrosis markers than GLP-1 mono-agonists, likely due to glucagon-mediated mitochondrial turnover and glycogenolysis.

If GLP-1 mono-agonists (like semaglutide) are not enough, dual agonists (like cotadutide or pemvidutide) may offer greater liver fat reduction and fibrosis improvement. However, these drugs are more complex and may cause more side effects. They are currently in clinical trials and not yet standard care. Discuss with your hepatologist if you are a candidate for these newer agents, especially if you have significant liver fat but stable diabetes.

Semaglutide use is associated with a high incidence of gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, with signal strength varying by clinical priority and time-to-onset.

If you are taking semaglutide, expect gastrointestinal side effects like nausea, vomiting, or diarrhea, especially when starting or increasing the dose. These are common and often decrease over time. Discuss starting with a lower dose and titrating slowly with your provider to improve tolerance. Ensure you stay hydrated and eat smaller, bland meals if symptoms occur.

Gut microbiota dysbiosis in obesity contributes to low-grade inflammation and increased fat storage through mechanisms including increased gut permeability (leaky gut), systemic lipopolysaccharide (LPS) circulation, and altered signaling of satiety hormones (GLP-1, PYY, ghrelin) via the gut-brain axis.

Focus on dietary fiber and diverse plant foods to support a healthy gut microbiome, which may help regulate satiety hormones and reduce inflammation. While not a standalone cure, this biological lever supports overall metabolic health.

Six months of once-weekly GLP-1 analogue (semaglutide) therapy restores natural killer (NK) cell effector function (cytotoxicity and cytokine production) in people with obesity, independent of weight loss.

For people with obesity, GLP-1 therapy (like semaglutide) may strengthen the immune system's ability to fight viruses and cancer, independent of how much weight is lost. This suggests benefits beyond just metabolic health.

GLP-1 therapy restores NK cell metabolism by upregulating the CD98-mTOR-glycolysis axis, which is critical for NK cell cytokine production.

GLP-1 therapy helps fix the 'metabolic engine' of immune cells (NK cells) in obese individuals, allowing them to produce necessary defense chemicals (cytokines) more effectively.

Cholecystokinin (CCK) attenuates reward-related signaling and motivation for food, acting as a satiety signal that can block the acquisition of conditioned place preference associated with rewarding stimuli.

Satiety hormones like CCK don't just turn off hunger; they can also reduce the reward value of food, making it less appealing.

GLP-1 receptor agonists should be discontinued prior to metabolic bariatric surgery to prevent delayed gastric emptying and aspiration pneumonia during anesthesia.

If you take GLP-1 medications (like Ozempic or Saxenda) and are having bariatric surgery, you MUST stop them before the procedure. Daily users should stop on the day of surgery; weekly users should stop one week prior. This prevents life-threatening aspiration pneumonia.

Strict glycemic control is the only intervention proven to prevent or delay the development of diabetic neuropathy in patients with type 2 diabetes.

If you have Type 2 Diabetes, keeping your blood sugar strictly under control is the most important thing you can do to prevent nerve damage (neuropathy). While other drugs and lifestyle changes are used, strict glucose management is the only proven way to stop or slow this specific complication. Regular foot checks and patient education are also critical to catch issues early.

Saturated fats do not cause cardiovascular disease; instead, coronary heart disease is driven by silent inflammation resulting from insufficient omega-3s, excessive omega-6s, and high fructose intake.

Stop fearing natural saturated fats like those in butter and meat. Instead, focus on reducing processed foods, sugar (especially fructose), and industrial trans fats. Ensure you get enough omega-3s from fish or supplements to manage inflammation, as this is the true driver of heart disease, not the saturated fat itself.

Palmitic acid is only harmful when produced endogenously via de novo lipogenesis from excess fructose; dietary palmitic acid is not the primary culprit for metabolic issues.

You don't need to strictly avoid dietary palmitic acid (found in meat, butter, palm oil). The real danger is consuming too much fructose (sugar, juice), which your liver converts into palmitic acid, causing inflammation. Reduce sugar, and your body handles saturated fats much better.

GLP-1 receptor agonists (GLP-1RAs) exert immunoregulatory effects by promoting the polarization of macrophages and microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, thereby reducing neuroinflammation and systemic inflammatory markers.

If you are using a GLP-1RA (like semaglutide or liraglutide) for diabetes or weight loss, understand that it may also be helping to lower systemic inflammation by shifting your immune cells toward a less inflammatory state. This is not just a side effect but a direct mechanism of action on your immune system.

GLP-1RAs modulate T cell differentiation by reducing the proportion of pro-inflammatory Th17 cells and increasing regulatory T cells (Tregs), thereby improving immune tolerance and reducing inflammation in conditions like psoriasis and colitis.

For those with autoimmune conditions, GLP-1RAs may help rebalance your immune system by reducing inflammatory T cells and boosting regulatory ones. This could potentially complement standard treatments by addressing the underlying immune imbalance.

GLP-1RAs reduce innate allergic inflammation and eosinophilia by inhibiting the activity of Group 2 Innate Lymphoid Cells (ILC2s) and reducing the production of type 2 cytokines (IL-5, IL-13).

If you have allergic asthma, GLP-1RAs might help reduce the specific allergic inflammation driven by innate immune cells, potentially easing symptoms beyond just metabolic benefits.

GDF15, a member of the TGF-β superfamily, acts as a central regulator of appetite and a potential treatment for obesity by reducing food intake and stimulating lipolysis.

GDF15 is a hormone that reduces food intake and increases fat burning. Research suggests it could be a future treatment for obesity, offering a different mechanism from current drugs.

GLP-1-based therapies and SGLT2 inhibitors provide protective effects on the coronary microvascular compartment in diabetic patients, addressing coronary microvascular dysfunction (CMD).

If you have diabetes and signs of heart issues like chest pain or shortnessess of breath without blocked arteries (CMD), ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs are increasingly recognized to protect the small blood vessels in the heart, beyond just lowering blood sugar.

Long-term LCHF diet adaptation may lead to the early development of central fatigue during exercise due to elevated blood concentrations of non-esterified fatty acids (NEFA) and ammonia.

Be aware that switching to a low-carb diet might make you feel mentally tired or 'lethargic' during exercise, especially early on. This is due to changes in blood chemistry (fatty acids and ammonia) affecting your brain. This is a known potential downside of LCHF that may counteract physical benefits.

Endogenous GLP-1 secretion is stimulated by specific nutrient-sensing mechanisms in intestinal L-cells, including SGLT1 and KATP channels for carbohydrates, FFA1 and GPR119 for fats, and Pept1 and CaSR for proteins.

This paper explains the biological 'sensors' in your gut that trigger GLP-1 release when you eat carbs, fats, and proteins. While understanding these mechanisms (like SGLT1 for sugar or GPR119 for fat) is crucial for drug development, there are currently no standard dietary protocols to specifically target these receptors for therapeutic GLP-1 elevation. The paper highlights that while animal models show clear results, human applicability is still being researched.